vTv Therapeutics Inc. EV/Operating CF

EV/Operating CF of VTVT for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/Operating CF growth rates and interactive chart. A valuation metric that measures the enterprise value of a company compared to its operating cash flow. Operating cash flow (OCF) is the amount of cash generated by a company's normal business operations. It can be different from reported net income due to accrual accounting, that is expenses and revenues are recognized differently than cash is received. The cash going in and out of the business is what ultimately determines its financial health, so it's one of the most important metrics to watch. A low EV/OCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. EV/OCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.

Highlights and Quick Summary

Current EV/Operating CF of vTv Therapeutics Inc. is -2.22 (as of December 30, 2019)
  • EV/Operating CF for the quarter ending September 29, 2020 was -3.93 (a 11.27% increase compared to previous quarter)
  • Year-over-year quarterly EV/Operating CF increased by 85.09%
  • Annual EV/Operating CF for 2019 was -2.22 (a 58.7% increase from previous year)
  • Annual EV/Operating CF for 2018 was -1.4 (a 0.5% increase from previous year)
  • Annual EV/Operating CF for 2017 was -1.39 (a 788.15% increase from previous year)
Visit stockrow.com/VTVT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/Operating CF of vTv Therapeutics Inc.

Most recent EV/Operating CFof VTVT including historical data for past 10 years.

Interactive Chart of EV/Operating CF of vTv Therapeutics Inc.

vTv Therapeutics Inc. EV/Operating CF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -3.93 -3.53
2019 -2.22 -2.12 -1.76 -1.4 -2.22
2018 -1.4 -0.53 -0.74 -1.23 -1.4
2017 -1.39 -1.14 -0.68 -0.75 -1.39
2016 -0.16 -0.55 0.04 0.53 -0.16
2015 0.67 1.03 -11.81 -11.81 0.67
2014 -11.81 -11.81 -11.81
2013 -11.81

Business Profile of vTv Therapeutics Inc.

Sector: Healthcare
Industry: Biotechnology
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase II clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase II clinical trials to treat type 2 diabetes, as well as is in Phase II/III clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptidic agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing HPP737, HPP971, and HPP3033 for the treatment of chronic disease. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.